Advertisement

PharmacoEconomics Spanish Research Articles

, Volume 9, Issue 1, pp 23–34 | Cite as

Análisis económico de oxicodona LP/ naloxona LP en el manejo del dolor intenso y el estreñimiento asociado al tratamiento con opioides en España

  • Gálvez Rafael
  • Provencio Mariano
  • Sanz-Ortiz Jaime
  • Ribera Ma Victoria
  • Esteban Emilio
  • Collado Francisco
  • Vara Francisco
  • Díaz Pilar
  • Rocafort Javier
  • Cobo Manuel
  • Traseira Susana
  • Brosa Max
Artículo de Investigacón Original
  • 14 Downloads

Resumen

Introducción: El dolor es todavía un grave problema de salud. Los opioides están recomendados en el manejo del dolor, pero su eficacia analgésica se asocia a algunos efectos adversos. El estreñimiento inducido por opioides (EIO) es el efecto adverso más frecuente, con un profundo impacto en la calidad de vida. El objetivo de este estudio fue estimar las consecuencias clínicas y económicas del uso de oxicodona de liberación prolongada (LP)/naloxona LP comparado con el de oxicodona LP, en pacientes con dolor crónico y EIO.

Métodos: Se construyó un modelo farmacoeconómico para describir las consecuencias clínicas y económicas para cada opción terapéutica. El modelo está basado en resultados de los ensayos clínicos, información sobre el manejo del EIO obtenida de un panel de 10 expertos clínicos españoles y costes representativos del Sistema Nacional de Salud (SNS). El estudio se realizó desde la perspectiva del SNS.

Resultados: El análisis de costes desagregados muestra que el mayor coste de adquisición de oxicodona LP/naloxona LP casi se compensa con el menor uso de recursos sanitarios asociados al manejo del EIO. Oxicodona LP/naloxona LP se asoció a mayor ganancia en años de vida ajustados por calidad y a razones de coste por AVAC ganado de entre 4.904 € y 6.723 € dependiendo del horizonte temporal del análisis. Los análisis de sensibilidad univariante y probabilístico confirmaron la solidez de estos resultados.

Conclusiones: La utilización de oxicodona LP/naloxona LP para el tratamiento del dolor intenso en España se asocia a razones de coste-efectividad muy por debajo del umbral para considerar una intervención sanitaria eficiente en España.

Palabras clave

oxicodona LP naloxona LP coste-efectividad estreñimiento 

Abstract

Introduction: Pain is still a major health problem. Although opioids are recommended for treatment of moderate-to-severe pain, their efficacy is commonly associated to a number of adverse events. Opioid induced constipation (OIC) is the most frequent adverse event and has an important impact on patient’s quality of life. The aim of this study was to estimate the clinical and economic consequences of prolonged-release (PR) oxycodone/naloxone compared to PR oxycodone, in patients with chronic pain and OIC.

Methods: A pharmacoeconomic model was built to describe both the economic and clinical outcomes associated to each compared therapeutic option. The model was based on clinical trial results, expert opinion on the management of OIC and local unit costs for the National Health System (NHS).

Results: The cost analysis showed that the higher acquisition cost of oxycodone/naloxone was almost offset by the decrease in resource use to manage OIC. PR oxycodone/naloxone was associated with higher quality adjusted life years and incremental cost per QALY gained ratios between 4.904 € and 6.723 € depending on time horizon. Univariate and probabilistic sensitivity analyses confirmed the robustness of these results.

Conclusions: Use of PR oxycodone/naloxone to treat severe pain in Spain is associated to an incremental cost-effectiveness ratio far below the efficiency threshold commonly cited in Spain.

Keywords

oxycodone naloxone cost-effectiveness constipation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografía

  1. 1.
    Breivik H, Collett B, Ventafridda V et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10:287–333.PubMedCrossRefGoogle Scholar
  2. 2.
    ACP — American College of Physicians ah- CoME. American College of Physicians Ethics Manual, Part I: History of medical ethics, the physician and the patient, the physician’s relationship to other physicians, the physician and society. Annals of Internal Medicine 1984;101:129–137.Google Scholar
  3. 3.
    Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs. 2003;63:649–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182(5A Suppl):11S–18S.PubMedCrossRefGoogle Scholar
  5. 5.
    Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61:1181–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Twycross R, Wilcock A. Pain Relief In Symptom management in Advanced Cancer. Radcliff Medical Press Oxon England 2002 pp17–68.Google Scholar
  7. 7.
    Vanegas G, Ripamonti C. Sbanotto A et al. Side effects of morphine administration in cancer patients. Cancer Nurs 1998;21:289–297.PubMedCrossRefGoogle Scholar
  8. 8.
    Thorpe DM. Management of opioid-induced constipation. Curr Pain Headache Rep 2001;5:237–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542–54.PubMedGoogle Scholar
  10. 10.
    Wirz S, Klaschik E. Management of constipation in palliative care patients undergoing opioid therapy: Is polyethylene glycol an option? Am J Hosp Palliat Care 2005;22:375–81.PubMedCrossRefGoogle Scholar
  11. 11.
    Überall MA, Müller-Schwefe GHH. Opioid-induced constipation — A frequent and distressing side effect in daily practice affecting oral and transdermal opioid applications. Eur J Pain 2006;10:S172.CrossRefGoogle Scholar
  12. 12.
    Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006;74:1347–54.PubMedGoogle Scholar
  13. 13.
    Annunziata K, Bell T. Impact of opioid-induced constipation on patients and healthcare resource use. Eur J Pain 2006;10(Suppl.1):S172.Google Scholar
  14. 14.
    Simpson K, Leyendecker P, Hopp M. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin. 2008;12:3503–12.CrossRefGoogle Scholar
  15. 15.
    Lowenstein O, Leyendecker P, Hopp M et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531–43.PubMedCrossRefGoogle Scholar
  16. 16.
    Gisbert R y Brosa M. eSalud, Base de Datos de Costes Sanitarios en España. Barcelona: Oblikue Consulting, s.l.; 2010. Disponible en: http://www.oblikue.com/bddcostes [consultado mayo de 2010].Google Scholar
  17. 17.
    Canal J, Cobo M, Provencio M, Perez C, Perez C, Galvez R. Prevalence and severity of Opioid Induced Bowel Dysfunction symptoms and differences among strong opioids. DIO study. 6th Research Congress of the European Association for Palliative Care, Glasgow, UK 2010; Abstract A-238-0003-00673.Google Scholar
  18. 18.
    Rentz AM, Yu R, Muller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 2009;12:371–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Schutter U, Grunert S, Meyer C, Schmidt T, Nolte T. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin 2010;26:1377–87.PubMedCrossRefGoogle Scholar
  20. 20.
    Detsky AS, Naglie G, Krahn MD et al. Primer on medical decision analysis: Part-1-Getting started. Med Decis Making 1997;17:123–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Lux, EA, Kremers W and Leyendecker P. 2010, Long-term efficacy, safety and quality of life of oxycodone and naloxone in a prolonged release (PR) fixed combination tablet in patients with chronic pain: World Congress of Pain, PT 388.Google Scholar
  22. 22.
    Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72.PubMedCrossRefGoogle Scholar
  23. 23.
    Sacristán JA, Oliva J, Del Llano J et al. ¿Qué es una tecnología sanitaria eficiente en España? Gac.San 2002;16:334–43.Google Scholar
  24. 24.
    Klaschik E, Nauck F and Ostgathe C. Constipation-modern laxative therapy. Support.Care Cancer 2003;11:679–85.PubMedCrossRefGoogle Scholar
  25. 25.
    Schwarzer A, Nauck F, Klaschik E. Strong opioids and constipation. Schmerz 2005:19:214–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Bouvy ML, Buurma H, Egberts TC. Laxative prescribing in relation to opioid use and the influence of pharmacy-based intervention. J Clin Pharm Ther 2002;27:107–10.PubMedCrossRefGoogle Scholar
  27. 27.
    McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control 2004;11(3 Suppl):3–9.PubMedGoogle Scholar
  28. 28.
    Clemens KE and Mikus G. Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert.Opin.Pharmacother 2010;11:297–310.PubMedCrossRefGoogle Scholar
  29. 29.
    Schutter U, Grunert S, Meyer C et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/ naloxone: a large observational study under conditions of daily practice. Curr.Med.Res.Opin 2010;26:1377–87.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Gálvez Rafael
    • 1
  • Provencio Mariano
    • 2
  • Sanz-Ortiz Jaime
    • 3
  • Ribera Ma Victoria
    • 4
  • Esteban Emilio
    • 5
  • Collado Francisco
    • 6
  • Vara Francisco
    • 7
  • Díaz Pilar
    • 8
  • Rocafort Javier
    • 9
  • Cobo Manuel
    • 10
  • Traseira Susana
    • 11
  • Brosa Max
    • 12
  1. 1.Unidad de DolorHospital Universitario Virgen de las NievesGranadaEspaña
  2. 2.Servicio de Oncología MédicaHospital Universitario Puerta de Hierro MajadahondaMadridEspaña
  3. 3.Servicio de Oncología MédicaHospital Universitario Marqués de ValdecillaSantanderEspaña
  4. 4.Unidad de DolorHospital Universitario Vall d’HebronBarcelonaEspaña
  5. 5.Servicio de Oncología MédicaHospital Universitario Central de AsturiasOviedoEspaña
  6. 6.Unidad de DolorHospital Universitario Puerta del MarCádizEspaña
  7. 7.Centro Regional de Cuidados Paliativos y Tratamiento del DolorHospital Los MontalvosSalamancaEspaña
  8. 8.Unidad de DolorComplejo Hospitalario de PontevedraPontevedraEspaña
  9. 9.Dirección AsistencialHospital Centro de Cuidados LagunaMadridEspaña
  10. 10.Servicio de Oncología Médica Complejo Hospitalario Regional Carlos HayaMálagaEspaña
  11. 11.Departamento MédicoMundipharma Pharmaceuticals S.L.MadridEspaña
  12. 12.S.L.BarcelonaEspaña

Personalised recommendations